TECH OFFERS

Traditional methods of culturing organoids are labor-intensive, time-consuming, and limited in their ability to produce large quantities of organoids with consistent quality and characteristics. This technology enables the production of homogenized organoids of consistent quality. It utilizes specialized conditions to facilitate mass production and automate the cultivation of organoids derived from various tissues and organs, including the liver, kidney, lung, and brain. The IP addresses a need in the marketplace by providing a more efficient and cost-effective method of producing organoids. This technology reduces the time and cost of producing organoids while improving the reproducibility and scalability of the process. This can accelerate drug discovery and development, improve the accuracy of toxicology testing, enable the development of personalized medicine, and eventually replace the need for animal testing in the long-term vision of drug development. The technology provider will be producing the desired organoids as the end product with a further aim to enable a platform service for toxicity and efficacy testing when fully commercialized. The identity of the organoids will be validated by expression of relevant biomarkers. The end users of this technology are likely to be pharmaceutical companies, biotech firms, academic research institutions, and clinical laboratories. Overall, the technology has the potential to transform the way organoids are produced and used in the biomedical field. The technology owner is actively seeking for R&D collaboration to allow integration into existing protocols and testing with institutions, biotech companies and Contract Research Organizations (CROs). A bioink composition for organoids generation and characterisation Method for creating consistent cell droplets, culturing them in suspension, and sorting them by desired characteristics Cost-effective, leading to a 10x reduction in price Cryopreservation of organoids can be implemented for long-term storage and to ensure stable delivery This solution is intended to be a platform technology to be deployed in the biomedical industry, specifically in drug discovery on molecular drugs or gene therapies, toxicology testing, disease modeling, and personalized medicine, as well as CROs providing testing services and biotech firms developing early-stage drugs. The products that can be marketed based on this technology are organoid assays derived from various human tissues and organs, such as liver, kidney, lung, and brain. These organoids can be used for various applications, including: Testing drug toxicity and efficacy Investigating disease mechanisms and identifying drug targets Developing personalized therapies for patients The organoids market is projected to grow at a significant rate in the coming years, with an increasing demand for personalized medicine and improved drug discovery and toxicology testing methods. According to a report by MarketsandMarkets, the organoids market is expected to reach USD 1,642 million by 2025, growing at a CAGR of 20.4% from 2020 to 2025. The drug discovery outsourcing market was valued at USD 4.03 billion in 2020 and is also expected to grow at a compound annual growth rate (CAGR) of 7.8% from 2021 to 2028, according to a report by Grand View Research. The increasing demand for novel and effective drugs, the rising cost of in-house drug development, and the need to expedite drug development timelines are some of the key factors driving the growth of this market. Pharmaceutical and biotech companies, as well as academic research institutions, are among the key buyers of drug discovery outsourcing services. These companies outsource drug discovery services to Contract Research Organizations (CROs) and Contract Development and Manufacturing Organizations (CDMOs) to reduce costs and accelerate drug development timelines. The technology represents a significant improvement over the current state-of-the-art in organoid production. Currently, the most common methods for organoid production involve manual culturing, which is prone to variability and can be time-consuming and labor-intensive. Although some automation, such as the use of microfluidics and robotics, has been incorporated into organoid production, these methods are still limited in terms of organoid yield and quality. Our technology offers several advantages and differentiates itself from competitors in several ways: Scalability: One of the key advantages of this technology is its ability to scale up organoid production to an industrial level. The homogenization and suspension of organoids allow for efficient automation and mass production of organoids, reducing the time and cost of production. Standardization: The technology offers a more standardized and reproducible process for organoid production, reducing variability between batches and improving the accuracy of drug testing and development. Versatility: The technology can be applied to generate organoids from various organs and tissues, allowing researchers to study multiple disease models in a more comprehensive manner. This versatility allows for a wider range of applications and increases the potential market size. Cost-effectiveness: The streamlined process and scalability of the technology can lead to significant cost savings compared to other organoid production methods, making it more accessible to researchers and companies. Homogenized organoids, mass production, automation, drug discovery, toxicology testing, personalized medicine, reproducibility, scalability, transformative technology Healthcare, Pharmaceuticals & Therapeutics, Manufacturing, Additive Manufacturing, Life Sciences, Industrial Biotech Methods & Processes

Diabetes is a prevalent and growing health problem worldwide, affecting 1 in 10 people, with 90% of cases being type 2 diabetes. Congenital diabetes also affects 1 in 6 live births. In the next 20 years, diabetes is projected to increase by 46%. More than half a billion people are affected globally, 400,000 of them are in Singapore and if nothing is done by 2050, there will be one million diabetics patients in Singapore.   The company offers two technical solutions in form of a blended powder format: 1) Low Glycaemic Index (GI) and 2) Low Glycaemic Index (GI) with added protein.   The blend is plant-based, a source of protein, high in dietary fibre and replaces sugar from 20% to 100% in recipes across various food and beverage applications, it is versatile, high solubility, no alternation to original taste.   The solution is primarily targeted at Food Service sectors operators and manufacturers who seeks to penetrate the reduced sugar food & beverage market.  The technology consists of a proprietary blend (formulated by a renowned research institute based in Singapore) and consist of ingredients and composition that has clinically proven results of lowered GI. Affordable and cost effective compared to functional sugars No alteration to original taste of recipe Versatility of application due to its high solubility The applications include but are not limited to: Beverage Products (Bubble Tea, Ready-To-Drink, Pre-Packaged, Hot & Cold Beverages) Bakery Products (Cookies, Muffins, Pies, Tarts, Cakes, Brownies) Dairy (Milkshakes, Ice Creams, Gelato, Frozen Yogurt) Desserts (Asian & Western) The global reduced sugar food & beverage market size is at US$46.1bil, growing at CAGR of 9.53% in next 5 years, APAC is the fastest growing region, valued at US$12.9bil. It is a global movement to fight against diabetes through educational campaigns and government intervention. The Singapore Government decided to introduce mandatory nutrition labels and advertising prohibitions for Nutri-Grade beverages across all formats. The innovative solution offers immense versatility, catering to a broad spectrum of food items. Unlike the current state-of-the-art, which primarily focuses on baked goods and rice, the technology is not restricted to the same spectrum offered by competitors. The potential applications of the technology are limitless, offering a significant advantage over existing solutions. Furthermore, clinical trials have been conducted to validate the efficacy of the technology in food product sets them apart from the current state-of-the-art. In addition, the company possess the technological capabilities to demonstrate the effectiveness and efficacy of their solution across a broad range of food items. This ability to provide concrete evidence of their technology's efficacy offers a compelling advantage to customers looking to adopt innovative, effective, and reliable solutions to meet the demands of the growing diabetic and obese market. Low GI, Low Glycaemic Index, Low Glycaemic Load, Diabetics friendly, Low Glycemic Index, Obesity, Reduced sugar, Better for you, Keto friendly, Plant based, vegan, Healthier choice, HCS, Nutri grade, Halal certified Foods, Ingredients

Terahertz (THz) radiation is a form of electromagnetic radiation that lies in the frequency spectrum ranging between microwaves and infrared light. In the field of Non-Destructive Testing (NDT), THz radiation is utilised to inspect materials for imperfections or anomalies. THz radiation can penetrate numerous non-metallic materials and can reveal internal structures that are not visible in natural light or x-ray imaging. THz-based NDT finds applications in a variety of applicatins, including aerospace, electronics, and medical imaging. Each material possesses a unique fingerprint that enables its identification, differentiation, condition, quantification, and quality of materials through spectroscopy. This technology offer is a spectral sensing technique that utilises accessible terahertz technology. It includes a portable device equipped with industrial-grade sensors and cloud-based data analytics. The technology owner is keen to engage in R&D collaboration with industrial partners in various industries, including pharmaceuticals, food packaging quality inspection and public safety inspection.     The technology offer is a reliable solution for non-disruptive inspection and measurement of materials:  It boasts high accuracy and multi-layer penetration capabilities. The accuracy rate of 95% in laboratory conditions provides users with confidence in the results produced. The wide measurement range of 30μm to 100μm and beyond with an accuracy of approximately ±4μm makes it suitable for various applications. The multi-layer penetration capability of up to four layers of material allows for the inspection of layered materials or detection of defects within multiple layers. Designed to increase productivity and efficiency, the technology provides accurate measurements and multi-layer penetration capabilities for faster decision-making and efficient use of resources. The technology offer is versatile, suitable for quality control and inspection in the manufacturing, electronics, medical, and aerospace industries.   This technology offer can be expanded and deployed in various industry such as: Package inspection Security and screening Spectroscopy, medical imaging Material science, chemical analysis Food quality control Terahertz (THz) technology offers numerous advantages over other radiation-based technologies. One key benefit is its ability to penetrate non-conductive materials, making it useful for imaging and inspecting plastic, paper, wood, cloth, ceramics, and other materials. THz technology is also safe and non-radioactive, making it a preferred choice for imaging and analysis. THz technology is non-contact and non-destructive, making it an ideal tool for Non-Destructive Testing (NDT) applications. It can detect defects and flaws within materials without requiring physical contact and provides high-resolution images with sub-millimeter accuracy. THz technology is valuable for composition identification by analyzing the spectral fingerprints of materials, allowing for non-invasive identification and characterization of materials. This feature is useful for security, pharmaceuticals, and food analysis applications. The technology owner is keen to engage in R&D collaboration with industrial partners in various industries, including pharmaceuticals, food packaging quality inspection and public safety inspection. mmwave, terahertz Electronics, Sensors & Instrumentation, Radio Frequency

Plywood is a preferred material used in furniture and home building for its durability since the Egyptian and Roman times. In 2019, the world consumed 165 million cm3 of plywood and was responsible for the creation of more than 3 billion tons of CO2. Applications for plywood are widespread including construction, home, retail, and office interior works and furnishings such as cabinetry, woodworking, renovations, and outfitting. Regulations and protectionism to slow down deforestation plus the tightening of sustainable forestry management lessen the supply of logging for plywood.  As global demand continues to be strong, the search for a viable replacement for plywood has become more pressing. More importantly, it is important to find a non-wood-based replacement with similar performance to plywood. Plywood is desirable because of its superior performance properties. Alternatives like medium-density boards (mdf) and particle boards are made from recycled wood waste. Unfortunately, plywood can only be made from virgin wood and there are no direct replacements for plywood currently. This technology leverages the global abundance of lignocellulosic fibre waste which is the discarded waste material after the harvesting and production of palm oil, rice, and wheat. The technology transforms these lignocellulosic fibre wastes into a direct replacement for conventional plywood.  This provides a sustainable, economically viable, and environmentally friendly solution to the continuing demand for plywood and the resolution to the growing lignocellulosic fiber waste problem in agri-food-based countries all over the world. The technology owner is open to various forms of collaboration including IP licensing, R&D collaboration, and test-bedding with different types of agrifood sidestreams. In the case of palm biomass waste, rice, and wheat straw waste, the technology is ready for commercialization. Produced material comparable to Grade A plywood in all performance parameters including modulus of rupture (MOR), modulus of elasticity (MOE), and water swelling Lower CAPEX & OPEX compared to producing conventional plywood Conversion process able to utilize standard commercial manufacturing equipment Activates the lignin within the agricultural biomass and transforms it into a 'natural superglue’ without commonly used formaldehyde-based binders Utilizes a series of hot presses under swinging and cyclical pressures and temperatures Construction Furniture Packaging Sports Equipment Automotive Industry Marine Industry Based on market research, the plywood industry is projected to experience significant growth from $54.79 billion in the current year to $85.26 billion by 2027, at a compound annual growth rate (CAGR) of 9.4%. With the increasing demand for sustainable materials and the valorization of agricultural waste, there is a potential opportunity for technology to emerge as a sustainable substitute for plywood in this expanding market. Sustainable solution as a direct replacement to plywood that reduces deforestation and recovers tremendous amounts of CO2 Non-added formaldehyde (NAF) Valorized plywood replacement comparable to Grade A plywood A credible global solution that contributes to reversing climate change Valorisation, agrifood, waste to worth, high value Waste Management & Recycling, Food & Agriculture Waste Management, Sustainability, Circular Economy

Capsule endoscopy is a non-invasive diagnostic method that utilizes a tiny, wireless camera capsule to capture images of the digestive system, which aids in identifying various conditions. Studies indicate that colon cancer is the leading cause of cancer-related deaths among men aged 20-49, and capsule endoscopy is the least invasive examination capable of detecting the early stages of this cancer, alongside other pathologies such as inflammatory bowel disease, ulcers, tumors, and gastro-intestinal bleeding. Without this procedure, these conditions often go undetected and become untreatable by the time noticeable symptoms appear. This technology offer is a remote capsule endoscopy examination, aiming to make colon diagnosis more widespread among people and extend its use to animals, primarily pets like dogs. Regular capsule endoscopy colon screenings are the only way to prevent the growth of undetectable pathologies. Remote technology enables patients to move around or work without needing to stay in a medical facility, allowing diagnoses to be conducted in areas previously unreachable by capsule endoscopy, such as on battlefields, in underdeveloped regions, or even by astronauts in space. The system includes an artificial intelligence module that automatically identifies and suggests potential pathologies in the images to the examining physician. This information assists doctors in quickly navigating through the collection of images, and it can help detect pathologies that may necessitate a more invasive diagnosis or immediate treatment. The technology owner is eager to engage in R&D collaboration with product development partners for gastro-intestinal endoscopic applications for both humans and animals. The AI-supported remote endoscopic capsule system is an innovative medical technology boasting several key features, such as: Remote diagnosis and examination: This system enables capsule endoscopy diagnosis and examination to occur at any location with a stable internet connection, eliminating the need for a specialized medical facility. Expanded examination scope: The examination monitors not only the small intestine but also the large intestine and stomach. Affordability: Examination costs for patients are several times lower than traditional capsule endoscopy, as the system uses significantly more affordable microcontrollers instead of costly, dedicated electronic components. Automatic pathology recognition: The system employs artificial intelligence algorithms to automatically detect pathologies, assisting doctors in diagnosing and reducing examination analysis time by an average of 3-4 times. High image resolution: The capsule utilizes cutting-edge optical technologies, enabling it to capture images with 50% higher resolution compared to competitors. Cloud storage connectivity: The system comes equipped with cloud storage connectivity, allowing easy access to patient data and images from anywhere globally. 94% effectiveness: This indicates that the system is highly successful in identifying and diagnosing medical conditions. 97.4% sensitivity: This high sensitivity rate means that the system is highly accurate in detecting potential health issues. This technology can be applied across various MedTech industry applications, such as: Gastroenterology: Useful for diagnosing and monitoring digestive tract conditions. Oncology: Valuable for detecting and monitoring cancers within the digestive tract. Sports Medicine: Applicable for diagnosing and monitoring injuries, including concussions, in sports medicine. Veterinary Medicine: Beneficial for diagnosing and monitoring digestive tract conditions in animals. This technology can also be further refined for use in the following applications: Industrial Inspection: Applicable in industries like oil and gas, aerospace, and manufacturing for remote visual inspections of internal structures and components, including pipelines, engines, and turbines. Military and Defense: Suitable for military and defence applications, such as inspecting hard-to-reach areas in aircraft or other vehicles. The technology offer boasts the following distinctive features: Remote control access: Accessible from any location worldwide with an internet connection. Affordability: Holds the potential to become a regular diagnostic tool. Minimally invasive: Eliminates the need for sedation or physically inserting a camera into the body, offering a less invasive alternative to traditional endoscopy procedures. Comfort: The procedure is painless and comfortable, with no requirement for anesthesia or sedation. Diagnostic accuracy: Delivers detailed images of the gastrointestinal tract that may not be visible using traditional endoscopy procedures, making it valuable for diagnosing conditions like inflammatory bowel disease, ulcers, and tumors. Convenience: Capsule endoscopy can be conducted in an outpatient setting, allowing patients to resume their normal activities immediately following the procedure. The technology owner is eager to engage in R&D collaboration with product development partners for gastro-intestinal endoscopic applications for both humans and animals. endoscopic, capsule-camera, diagnostics, non-invasive, remote, affordable Electronics, Sensors & Instrumentation, Healthcare, Diagnostics, Medical Devices

Smart Inhalers pose great potential in empowering disease management. Common difficulties faced by patients in the use of inhalers include inaccurate dosing, incorrect inhalation technique, insufficient deep inspiration flow rate and compliance. This technology aims to tackle the issue of over or underdosage delivery, device misuse and lack of monitoring or analytics found in current technologies. Using its proprietary precision dosing system, the device can accurately control dosages with an error rate of as low as 4% while enabling intelligent therapy monitoring and medical reporting for improved patient adherence and treatments. The device functions by breath-activated operation to prevent wastage, heat-free fine particle liquid nebulization for safer drug delivery and deeper lung deposition. It features a propellant-free compact (pocket-sized) smart inhaler with liquid drug cartridges designed to replace injections and modernize inhaled therapies using the lung as a platform for delivery, addressing the lack of pain-free, hassle-free, smart alternatives for various medications. Due to its proprietary atomizer that works on almost 90% of most liquid medication, it has significant potential to be scaled in various drug types and markets, such as insulin, antivirals, hormones, and smart intranasal delivery for neurological conditions.  The technology owner is actively seeking collaboration opportunities with commercialization partners, pharmaceutical, biotech, OEM, CRO companies, who can license it to bring it to market or integrate it into existing healthcare systems. This scalability makes the technology highly appealing to a wide range of potential partners and licensees including co-development for customization and R&D or joint venture.   Proprietary precision dosing system: Built-in circuitry that continuously monitors and controls consistent piezo's operation. Ensures accurate, stable, and quantifiable volume of liquids being atomized. Deep penetration and targeting: Patented technology engineers the piezo to stably operate around the optimal 2.5 microns for deep deposition into lungs. (Particles around 1 micron are exhaled because they are too light/small, particles above 4 microns are stuck in throat as they are too big/heavy). Programmable: Precision dosing can be controlled via device and phone by engineering a cut-off function so that device will not atomize when inhaled. Customization: Different formulations and multi-drug mixture in one pod or double cartridge delivery system. Flexibility: Options to deliver a wider range of medications, including micro-dosing (as low as 0.03ml/5secs) for more targeted and personalized treatment. Reducing the risk of adverse side effects and allowing for more effective treatment for sensitive patients. Heat-free and propellant-free nebulization: Does not affect medication degradation. Works with liquid medication (depends on viscosity of fluid). Breath-activated suction cap: Device does not have buttons. Intelligent therapy monitoring: The device automatically time stamps and captures each dose helping healthcare professionals track the progress of the therapy remotely. Liquid disposable cartridge system: Quick and hygienic medication replacement without the need for manual cleaning or maintenance of the inhaler. This reduces the risk of contamination or dosing errors. Patient-designed convenience: Non-removable rechargeable battery lasting up to one week before recharging. User friendly for patients to take their medication anytime and anywhere. Industries where this technology can be deployed include: Pharmaceutical and biotechnology companies Medical device manufacturers Healthcare providers and clinics Digital health platforms and telemedicine services Diabetes care Value added generic medicine Potential products based on this technology include: Broadening the arsenal of therapeutic options for the Health Care Providers New alternative to injections and current inhalation devices Smart intranasal delivery devices for neurological conditions and mental health treatments, increasing the potential for targeted drug delivery to the brain Integration with other health monitoring apps for better adherence and reporting (like continuous glucose monitors) Developing inhalable versions of pain-relief medications for patients who struggle with swallowing pills or require rapid onset of pain relief Smart inhalers for insulin delivery Faster and more efficient way to deliver antibiotics for respiratory infections, such as pneumonia or bronchitis, potentially reducing treatment duration and improving patient outcomes A more comfortable and less invasive method for administering vaccines, potentially increasing vaccination rates and improving public health Developing targeted inhalable chemotherapy or immunotherapy treatments for lung cancer or other respiratory-related malignancies, potentially reducing systemic side effects and increasing treatment efficacy The approximate market size for this smart inhaler technology can be substantial, given its potential applicability across various therapeutic areas. The global inhaler market was valued at around US$39.3 Billion in 2022 while the diabetes management market US$92.97 Billion. Considering the smart inhaler's ability to address both the pulmonary drug delivery and daily injection markets, the Total Available Market can be up to a US$1 Trillion adding up all the therapeutic areas. This proprietary smart inhaler technology represents a significant improvement over the current "State-of-the-Art" in drug delivery systems. Its unique value lies in its combination of precision dosing, versatility, and improved patient experience. Benefits for healthcare professionals and patients include: Ensuring accurate dose administration, driving therapy effectiveness Greater therapy monitoring and personalized care Differentiating drug offerings and broadening therapeutic options for healthcare providers Simplifying drug delivery, increasing patient satisfaction Intelligent therapy monitoring and medical reporting features leads to enhanced patient experience Health-economic benefits: Reducing waste and optimizing resource utilization Enhancing adherence, leading to better health outcomes and reduced healthcare costs Expanding the reach of insulin therapy to more people, addressing unmet needs Potential cost savings for payers Pricing flexibility that accounts for the benefits of the new application Benefits for partners: By maximizing drug portfolio potential, this technology allows pharmaceutical companies to diversify, differentiate, and defend against patent expiration, leading to improved patient outcomes and market growth Inhaled Drug Delivery, Medical Device, Remote Diagnostics, Patient-centric healthcare, Personalized medicine, Nebulization, Patent-protected technology, Alternative to injections, Chronic disease management, Digital health innovation Electronics, Sensors & Instrumentation, Healthcare, Medical Devices, Telehealth, Medical Software & Imaging, Pharmaceuticals & Therapeutics, Life Sciences, Industrial Biotech Methods & Processes

Pressure sensitive adhesives (PSAs) are viscous resins that are designed to adhere to various substrates under light pressure. Majority of commercially available PSAs are derived from non-renewable petroleum sources such as acrylics and silicones, providing the required bonding performance for either permanent or removable applications for use in labels and packaging. However, conventional PSAs present environmental concerns at their end of life, even when its substrate is biodegradable. The technology on offer is a patented bio-based, compostable PSAs comprising of 95% soy and other bio-derived materials that costs less than petroleum adhesives. These PSAs can bond to a variety of substrates (including paper and foams), contains no solvent or water, lowers CO2 emissions when compared to conventional PSA. It can be applied using standard application techniques (slot die or gravure systems) and upon curing will result in a light, cream coloured film. The technology owner is seeking for R&D collaborations and IP licensing opportunities with Singapore partners to manufacture/utilise the technology in packaging and non-structural applications. The technology is a soy-based, hot melt PSA that enables excellent adhesion to a variety of substrates. Some features of the technology include: Does not contain water or solvent Comparable adhesive performance to petroleum-based PSAs Net negative CO2 emissions - 0.79kg CO2 sequestered per 1 kg manufactured Costs 20% less than competing petroleum-based PSAs Home compostable (ASTM 6400/EN 13432) and industrial compostable (ASTM 5511) Applied using standard application techniques such as slot die and gravure systems Can be UV or thermal cured Can be designed to be removable or permanent for labels and tapes Potential applications include (but are not limited to): Packaging such as flexible and paper-based Tapes Labels Protective films Commercial applications that require compostable, bio-based alternatives to acrylic The pressure sensitive adhesives market is projected to grow from USD 13.2 billion in 2022 to USD 16.9 billion by 2027, at a CAGR of 5.1% between 2022 and 2027. With this technology, companies will be able to move away from fossil-based PSAs and achieve their environmental, social and governance goals to combat climate change. Use of renewable, bio-based raw materials that is compostable Cost-effective solution that meets the performance of conventional PSAs Helps corporations meet sustainability objectives by reducing carbon footprint The technology owner is seeking for R&D collaborations and IP licensing opportunities with Singapore partners to manufacture/utilise the technology in packaging and non-structural applications. adhesive, packaging, compostable, bio-based, environmentally friendly, sustainable, pressure sensitive, soy, bonding, tape, label, eco-friendly, films, paper, plastic packaging, circular economy, reduced carbon emissions Manufacturing, Chemical Processes, Chemicals, Organic, Bio-based, Sustainability, Circular Economy

Asia accounts for approximately 70% of the world’s seafood consumption, around 69.6 million metric tons. This is more than twice the total amount consumed by the rest of the world.* Commercially, about 30% of the seafood is not consumed, from bones to offals, to skin/shell/scales. These food loss and waste potentially impose environmental and socioeconomic issues.  The technology provider has developed a green chemical process converting seafood sidestreams into food products that are not only high value but also nutritious, addressing Singapore’s demand to increase production of nutrient dense foods. In addition, this method is efficient and cost effective as it requires basic equipment. The technology provider is looking for R&D collaborators and for test-bedding especially with industries who are producing aquaculture food with high nutritional value and interested to utilise their sidestreams more sustainably. * FAO 2018 The technology covers waste valorization, food technology, converting them into sustainable high value food. Some key features of the technology are as follows: Low cost production Rich in nutrition which is comparable to commercial high value food Tunable textures and properties Simple processes and equipment needed Product is thermally stable Foods (e.g. collagen rich foods, protein rich products) Supplements to provide amino acids  Customizable solutions achieving high value and nutritious foods with good thermal stability Extremely high yield (>80%) Environmentally sustainable food production through food sidestream valorization Low energy and low cost of production using simple processing methods Scalable process High value food, Aquaculture side stream, Alternative source of protein Materials, Bio Materials, Foods, Processes, Waste Management & Recycling, Food & Agriculture Waste Management, Sustainability, Sustainable Living, Food Security

The conventional DC brushless motors face the challenge of reduced output when their size is reduced to achieve a smaller product, as well as the difficulty of precise control according to the load. A unique solution to these problems would be the use of compact, high-power DC brushless motors with vector control technology. These current issues contributed to the product developers in the creation of more compact and lightweight products that offer improved performance and increased functionality by responding to load-specific characteristics. With vector control technology, these motors provide precise control over motor speed and torque, resulting in enhanced efficiency and reduced energy consumption. The benefits of using these motors include improved product design, increased functionality, and greater efficiency The technology offer comprises of two portions of the motor internal structural design and the use of vector control technology to maximize the performance of the overall system.  These unique motors control system offers a reliable and effective solution to the challenges faced by conventional DC brushless motors. The technology owner is keen to do R&D collaboration and licensing out the know-how to a variety of applications such as robotics, electric vehicles, and industrial automation systems.    The main features of the technology offer are: 1. Compact and lightweight: The motor's compactness and high-power output are achieved by improving the space factor using split iron core structure Ability to achieve about 40% reduction in physical size of motor while maintain the power output Weight of the motor can achieve reduction of about 25% Output power increased by upto 60% compared to the similar-sized motors 2. Precision drive control according to load fluctuations by vector control: The motor can be controlled to the optimum speed and torque according to the load by monitoring the motor load from the individual current values across the three phases. Optimum drive control can achieve 10% increase in working speed and 15% increase in workload 3. Environmental resistance performance: Waterproof and dustproof performance equivalent to IP56, making it suitable for machine tools and equipment used outdoors. The technology offer can be customised and adopted in various application that uses compact brushless DC motors, such as: Personal Mobility: Electric bicycles Electric kickboards Electric baby car Material Handling: Automatic guided vehicles (AGV) Electric power-assisted trolleys Personal and Commercial Automation: Electric doors Platform screen doors Electric garage gates Non-residential automatic doors Electric reels for fishing Automatic cleaning robots Electric massage chairs Industrial and Manufacturing: Machine tools (drill press, NC lathe, screw fastener, drill machine) Power tools The split stator core structure of the motor allows it to be smaller and lighter without compromising its ability to handle increased power output. This feature enables products that use the motor to maintain their performance while becoming more compact and lightweight. Alternatively, the motor can be used to enhance the product's performance without increasing its size. Furthermore, the motor's high-function control system allows it to adjust its performance based on the load. For instance, it can control the number of revolutions or stop according to the load. This capability enables the addition of new product features, which can lead to increased functionality and versatility. Additionally, the motor's robustness against water and dust makes it suitable for products used in harsh environments, such as outdoor settings. This feature enhances the durability and reliability of the product and extends its lifespan. The technology owner is keen to do R&D collaboration and licensing out the know-how to a variety of applications developers such as robotics, electric vehicles, and industrial automation systems.    brushless DC motor, compact motor, vector control, load detection, split stator core, waterproof motor, dustproof motor, power tools Electronics, Actuators, Power Management